Why Pfizer (PFE) Shares Are Trading Lower Premarket Today - Pfizer (NYSE:PFE)

Pfizer Inc PFE has reported a Q4 adjusted EPS of $1.14, up 45% Y/Y, well ahead of the consensus of $1.05.
The company achieved revenues of $24.29 billion, up 2% and 13% on an operational basis, marginally missing the Wall Street estimate of $24.32 billion.
For FY22, Pfizer's $100.3 billion revenues are at an all-time high, reflecting 30% operational growth.
Excluding contributions from Paxlovid and Comirnaty, revenues grew 2% operationally.
FY23 Outlook: Pfizer forecasts FY23 sales to fall to $67-$71 billion from $100 billion in 2022 versus the consensus of $74.13 billion.
The company expects adjusted EPS guidance of $3.25-$3.45, down from $6.58 in 2022 and the consensus of $4.44.
Pfizer expects sales of $13.5 billion from the COVID-19 vaccine for 2023 and projected $8 billion in sales of its antiviral pill, Paxlovid. That compared with sales of $37.81 billion for the vaccine and $18.93 billion for Paxlovid in 2022.
Price Action: PFE shares are down 2.99% at $42.25 during the premarket session on the last check Tuesday.

Overview Rating:

Speculative

0100

Pfizer Beats Q4 Earnings, Issues Underwhelming 2023 Guidance